Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lynn E. DeLisi is active.

Publication


Featured researches published by Lynn E. DeLisi.


American Journal of Human Genetics | 2003

Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia

Cathryn M. Lewis; Douglas F. Levinson; Lesley H. Wise; Lynn E. DeLisi; Richard E. Straub; Iiris Hovatta; Nigel Melville Williams; Sibylle G. Schwab; Ann E. Pulver; Stephen V. Faraone; Linda M. Brzustowicz; Charles A. Kaufmann; David L. Garver; Hugh Gurling; Eva Lindholm; Hilary Coon; Hans W. Moises; William Byerley; Sarah H. Shaw; Andrea Mesén; Robin Sherrington; F. Anthony O'Neill; Dermot Walsh; Kenneth S. Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael Conlon O'Donovan; Michael John Owen

Schizophrenia is a common disorder with high heritability and a 10-fold increase in risk to siblings of probands. Replication has been inconsistent for reports of significant genetic linkage. To assess evidence for linkage across studies, rank-based genome scan meta-analysis (GSMA) was applied to data from 20 schizophrenia genome scans. Each marker for each scan was assigned to 1 of 120 30-cM bins, with the bins ranked by linkage scores (1 = most significant) and the ranks averaged across studies (R(avg)) and then weighted for sample size (N(sqrt)[affected casess]). A permutation test was used to compute the probability of observing, by chance, each bins average rank (P(AvgRnk)) or of observing it for a bin with the same place (first, second, etc.) in the order of average ranks in each permutation (P(ord)). The GSMA produced significant genomewide evidence for linkage on chromosome 2q (PAvgRnk<.000417). Two aggregate criteria for linkage were also met (clusters of nominally significant P values that did not occur in 1,000 replicates of the entire data set with no linkage present): 12 consecutive bins with both P(AvgRnk) and P(ord)<.05, including regions of chromosomes 5q, 3p, 11q, 6p, 1q, 22q, 8p, 20q, and 14p, and 19 consecutive bins with P(ord)<.05, additionally including regions of chromosomes 16q, 18q, 10p, 15q, 6q, and 17q. There is greater consistency of linkage results across studies than has been previously recognized. The results suggest that some or all of these regions contain loci that increase susceptibility to schizophrenia in diverse populations.


Nature Genetics | 2009

Microduplications of 16p11.2 are associated with schizophrenia.

Shane McCarthy; Vladimir Makarov; George Kirov; Anjene Addington; Jon McClellan; Seungtai Yoon; Diana O. Perkins; Diane E. Dickel; Mary Kusenda; Olga Krastoshevsky; Verena Krause; Ravinesh A. Kumar; Detelina Grozeva; Dheeraj Malhotra; Tom Walsh; Elaine H. Zackai; Jaya Ganesh; Ian D. Krantz; Nancy B. Spinner; Patricia Roccanova; Abhishek Bhandari; Kevin Pavon; B. Lakshmi; Anthony Leotta; Jude Kendall; Yoon-ha Lee; Vladimir Vacic; Sydney Gary; Lilia M. Iakoucheva; Timothy J. Crow

Recurrent microdeletions and microduplications of a 600-kb genomic region of chromosome 16p11.2 have been implicated in childhood-onset developmental disorders. We report the association of 16p11.2 microduplications with schizophrenia in two large cohorts. The microduplication was detected in 12/1,906 (0.63%) cases and 1/3,971 (0.03%) controls (P = 1.2 × 10−5, OR = 25.8) from the initial cohort, and in 9/2,645 (0.34%) cases and 1/2,420 (0.04%) controls (P = 0.022, OR = 8.3) of the replication cohort. The 16p11.2 microduplication was associated with a 14.5-fold increased risk of schizophrenia (95% CI (3.3, 62)) in the combined sample. A meta-analysis of datasets for multiple psychiatric disorders showed a significant association of the microduplication with schizophrenia (P = 4.8 × 10−7), bipolar disorder (P = 0.017) and autism (P = 1.9 × 10−7). In contrast, the reciprocal microdeletion was associated only with autism and developmental disorders (P = 2.3 × 10−13). Head circumference was larger in patients with the microdeletion than in patients with the microduplication (P = 0.0007).


Psychiatry Research-neuroimaging | 1997

Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia

Lynn E. DeLisi; Michael Sakuma; William Tew; Maureen Kushner; Anne L. Hoff; Roger Grimson

Brain structural deviation is known to be present in chronic patients with schizophrenia when compared with normal age-matched individuals. While the assumption is that these differences are based on a neurodevelopmental disturbance, whether they are static or continue to change throughout the disease process remains unknown. The following report describes a prospective follow-up study of first episode cases of schizophrenic illness. Analyses of MRI evaluations on an approximate annual basis for a minimum of four years are presented on 50 patients and 20 controls. Computer-assisted image analysis measuring the volume of several brain regions, using the program ANALYZE (Mayo Clinic), was performed on all scans. Patients were compared with controls for the rate of change over time in size of structures. No differences were found for the volumes of the caudate nucleus, temporal lobes, or hippocampus; and no changes in the degree of cerebral laterality were detected. However, there was a significant difference in the rate of change in the overall volumes of left and right hemispheres (P < 0.0004 and 0.001, respectively), right cerebellum (P < 0.02) and area of the isthmus of the corpus callosum (P < 0.05). The left cerebral ventricle had significantly greater enlargement over time when measured on coronal slice sequences (P < 0.02), but was not detected by axial views. These findings suggest that a subtle active brain process may be continuing through the first few years of a schizophrenic illness causing greater than the normal adult cortical deterioration. Further studies using other methods of image analysis and over a longer period of time are needed to determine the course and nature of this biologic process.


Nature Genetics | 2010

A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay

Santhosh Girirajan; Jill A. Rosenfeld; Gregory M. Cooper; Francesca Antonacci; Priscillia Siswara; Andy Itsara; Laura Vives; Tom Walsh; Shane McCarthy; Carl Baker; Mefford Hc; Jeffrey M. Kidd; Sharon R. Browning; Brian L. Browning; Diane E. Dickel; Deborah L. Levy; Blake C. Ballif; Kathryn Platky; Darren M. Farber; Gordon C. Gowans; Jessica J. Wetherbee; Alexander Asamoah; David D. Weaver; Paul R. Mark; Jennifer N. Dickerson; Bhuwan P. Garg; Sara Ellingwood; Rosemarie Smith; Valerie Banks; Wendy Smith

We report the identification of a recurrent, 520-kb 16p12.1 microdeletion associated with childhood developmental delay. The microdeletion was detected in 20 of 11,873 cases compared with 2 of 8,540 controls (P = 0.0009, OR = 7.2) and replicated in a second series of 22 of 9,254 cases compared with 6 of 6,299 controls (P = 0.028, OR = 2.5). Most deletions were inherited, with carrier parents likely to manifest neuropsychiatric phenotypes compared to non-carrier parents (P = 0.037, OR = 6). Probands were more likely to carry an additional large copy-number variant when compared to matched controls (10 of 42 cases, P = 5.7 × 10−5, OR = 6.6). The clinical features of individuals with two mutations were distinct from and/or more severe than those of individuals carrying only the co-occurring mutation. Our data support a two-hit model in which the 16p12.1 microdeletion both predisposes to neuropsychiatric phenotypes as a single event and exacerbates neurodevelopmental phenotypes in association with other large deletions or duplications. Analysis of other microdeletions with variable expressivity indicates that this two-hit model might be more generally applicable to neuropsychiatric disease.


Biological Psychiatry | 1991

Brain morphology in first-episode schizophrenic-like psychotic patients : a quantitative magnetic resonance imaging study

Lynn E. DeLisi; Anne L. Hoff; Joseph E. Schwartz; Gail Shields; Srinivas N. Halthore; Simhardi M. Gupta; Fritz A. Henn; Azad K. Anand

Brain morphology was examined using magnetic resonance imaging in 30 first-episode patients with a schizophreniclike psychosis, 15 chronic schizophrenics, and 20 neurological controls. Statistical analyses of computer-generated measurements of regions of interest were controlled for gender, age, social class, and total brain volume. Lateral ventricular size was increased in both first-episode and chronic schizophrenic patients, with greater significance on the left than on the right side. Only the chronic patients, however, had reduced temporal lobe size, which also was greater on the left side. No major correlations of regional brain morphological measurements with cognitive functioning were found, although some measurements of verbal memory were correlated with parahippocampal size. This is a report of a preliminary study that suggests that some morphological brain changes may be present at the time of first treatment for a psychotic illness, whereas others may occur later in the course of illness. Future prospective studies may determine the clinical significance of these changes and whether they progress with the development of illness chronicity.


Journal of Affective Disorders | 1986

Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness.

M.S. Buchsbaum; Joseph Wu; Lynn E. DeLisi; Henry H. Holcomb; Ronald C. Kessler; Jeannette L. Johnson; King Ac; Erin A. Hazlett; K. Langston; Robert M. Post

Twenty affective disorder patients (16 bipolar and 4 unipolar) and 24 normal controls received scans with positron emission tomography (PET) using [18F]2-deoxyglucose (FDG) as a tracer. Subjects received a series of brief electrical stimuli to their right arms during FDG uptake. Patients with bipolar affective illness had significantly lower frontal to occipital glucose metabolic rate ratios (relative hypofrontality) and significantly lower metabolic rates in their basal ganglia in comparison to whole slice metabolism than normal controls. Patients with unipolar illness showed significantly higher frontal to occipital ratios, and also showed relatively decreased metabolism in the basal ganglia. All results in unipolar patients should be considered exploratory due to the small number of patients. Clinical depression ratings correlated negatively with whole slice metabolic rate.


Molecular Psychiatry | 2007

LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia

Clyde Francks; S. Maegawa; Juha Laurén; Brett S. Abrahams; Antonio Velayos-Baeza; Sarah E. Medland; S. Colella; Matthias Groszer; E. Z. McAuley; Tara M. Caffrey; T. Timmusk; P. Pruunsild; I. Koppel; Penelope A. Lind; N. Matsumoto-Itaba; Jérôme Nicod; Lan Xiong; Ridha Joober; Wolfgang Enard; B. Krinsky; E. Nanba; Alex J. Richardson; Brien P. Riley; Nicholas G. Martin; Stephen M. Strittmatter; H.-J. Möller; Dan Rujescu; D. St Clair; Pierandrea Muglia; J. L. Roos

Left–right asymmetrical brain function underlies much of human cognition, behavior and emotion. Abnormalities of cerebral asymmetry are associated with schizophrenia and other neuropsychiatric disorders. The molecular, developmental and evolutionary origins of human brain asymmetry are unknown. We found significant association of a haplotype upstream of the gene LRRTM1 (Leucine-rich repeat transmembrane neuronal 1) with a quantitative measure of human handedness in a set of dyslexic siblings, when the haplotype was inherited paternally (P=0.00002). While we were unable to find this effect in an epidemiological set of twin-based sibships, we did find that the same haplotype is overtransmitted paternally to individuals with schizophrenia/schizoaffective disorder in a study of 1002 affected families (P=0.0014). We then found direct confirmatory evidence that LRRTM1 is an imprinted gene in humans that shows a variable pattern of maternal downregulation. We also showed that LRRTM1 is expressed during the development of specific forebrain structures, and thus could influence neuronal differentiation and connectivity. This is the first potential genetic influence on human handedness to be identified, and the first putative genetic effect on variability in human brain asymmetry. LRRTM1 is a candidate gene for involvement in several common neurodevelopmental disorders, and may have played a role in human cognitive and behavioral evolution.


Proceedings of the National Academy of Sciences of the United States of America | 2010

De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia

Julie Gauthier; Nathalie Champagne; Ronald G. Lafrenière; Lan Xiong; Dan Spiegelman; Edna Brustein; Mathieu Lapointe; Huashan Peng; Mélanie Côté; Anne Noreau; Fadi F. Hamdan; Anjene Addington; Judith L. Rapoport; Lynn E. DeLisi; Marie-Odile Krebs; Ridha Joober; Ferid Fathalli; Fayçal Mouaffak; Ali P. Haghighi; Christian Neri; Marie-Pierre Dubé; Mark E. Samuels; Claude Marineau; Eric A. Stone; Philip A. Barker; Salvatore Carbonetto; Pierre Drapeau; Guy A. Rouleau

Schizophrenia likely results from poorly understood genetic and environmental factors. We studied the gene encoding the synaptic protein SHANK3 in 285 controls and 185 schizophrenia patients with unaffected parents. Two de novo mutations (R1117X and R536W) were identified in two families, one being found in three affected brothers, suggesting germline mosaicism. Zebrafish and rat hippocampal neuron assays revealed behavior and differentiation defects resulting from the R1117X mutant. As mutations in SHANK3 were previously reported in autism, the occurrence of SHANK3 mutations in subjects with a schizophrenia phenotype suggests a molecular genetic link between these two neurodevelopmental disorders.


American Journal of Medical Genetics | 1998

A genome-wide search for schizophrenia susceptibility genes

Sarah H. Shaw; Mary Kelly; Angela B. Smith; Gail Shields; Penelope J. Hopkins; Josephine Loftus; Steven Laval; Antonio Vita; Marc De Hert; Lon R. Cardon; Timothy J. Crow; Robin Sherrington; Lynn E. DeLisi

We completed a systematic genome-wide search for evidence of loci linked to schizophrenia using a collection of 70 pedigrees containing multiple affected individuals according to three phenotype classifications: schizophrenia only (48 pedigrees; 70 sib-pairs); schizophrenia plus schizoaffective disorder (70 pedigrees; 101 sib-pairs); and a broad category consisting of schizophrenia, schizoaffective disorder, paranoid or schizotypal personality disorder, psychosis not otherwise specified (NOS), delusional disorder, and brief reactive psychosis (70 pedigrees; 111 sib-pairs). All 70 families contained at least one individual affected with chronic schizophrenia according to DSM-III-R criteria. Three hundred and thirty-eight markers spanning the genome were typed in all pedigrees for an average resolution of 10.5 cM (range, 0-31 cM) and an average heterozygosity of 74.3% per marker. The data were analyzed using multipoint nonparametric allele-sharing and traditional two-point lod score analyses using dominant and recessive, affecteds-only models. Twelve chromosomes (1, 2, 4, 5, 8, 10, 11, 12, 13, 14, 16, and 22) had at least one region with a nominal P value <0.05, and two of these chromosomes had a nominal P value <0.01 (chromosomes 13 and 16), using allele-sharing tests in GENEHUNTER. Five chromosomes (1, 2, 4, 11, and 13) had at least one marker with a lod score >2.0, allowing for heterogeneity. These regions will be saturated with additional markers and investigated in a new, larger set of families to test for replication.


Nature | 2011

Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia

Vladimir Vacic; Shane McCarthy; Dheeraj Malhotra; Fiona Murray; Hsun Hua Chou; Aine Peoples; Vladimir Makarov; Seungtai Yoon; Abhishek Bhandari; Roser Corominas; Lilia M. Iakoucheva; Olga Krastoshevsky; Verena Krause; Verãnica Larach-Walters; David K. Welsh; David Craig; John R. Kelsoe; Elliot S. Gershon; Suzanne M. Leal; Marie Dell Aquila; Derek W. Morris; Michael Gill; Aiden Corvin; Paul A. Insel; Jon McClellan; Mary Claire King; Maria Karayiorgou; Deborah L. Levy; Lynn E. DeLisi; Jonathan Sebat

Rare copy number variants (CNVs) have a prominent role in the aetiology of schizophrenia and other neuropsychiatric disorders. Substantial risk for schizophrenia is conferred by large (>500-kilobase) CNVs at several loci, including microdeletions at 1q21.1 (ref. 2), 3q29 (ref. 3), 15q13.3 (ref. 2) and 22q11.2 (ref. 4) and microduplication at 16p11.2 (ref. 5). However, these CNVs collectively account for a small fraction (2–4%) of cases, and the relevant genes and neurobiological mechanisms are not well understood. Here we performed a large two-stage genome-wide scan of rare CNVs and report the significant association of copy number gains at chromosome 7q36.3 with schizophrenia. Microduplications with variable breakpoints occurred within a 362-kilobase region and were detected in 29 of 8,290 (0.35%) patients versus 2 of 7,431 (0.03%) controls in the combined sample. All duplications overlapped or were located within 89 kilobases upstream of the vasoactive intestinal peptide receptor gene VIPR2. VIPR2 transcription and cyclic-AMP signalling were significantly increased in cultured lymphocytes from patients with microduplications of 7q36.3. These findings implicate altered vasoactive intestinal peptide signalling in the pathogenesis of schizophrenia and indicate the VPAC2 receptor as a potential target for the development of new antipsychotic drugs.

Collaboration


Dive into the Lynn E. DeLisi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne L. Hoff

University of California

View shared research outputs
Top Co-Authors

Avatar

Richard Jed Wyatt

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lynn R. Goldin

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge